US › Healthcare

Biovie Inc (BIVI)

US · Healthcare · Biotechnology

$1.78+3.49%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-5.6M

EPS

$-0.70

EPS estimate

$-0.52

EPS came in at -0.70 against a street estimate of -0.52 — a miss of 34.6%.

Key statistics

Market cap

$16.3M

Forward P/E

0.0

P/B

1.59

Book value

$1.36

EPS (TTM)

$-3.05

52-week high

$3.79

52-week low

$0.82

50-day MA

$1.73

200-day MA

$1.51

Beta

0.74

Analyst view

Analysts rate Biovie Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $5.25.

Shareholding

Insiders

0.60%

Institutions

25.16%

Largest institutional holders

Fund	Stake
Diametric Capital, LP	4.38%
Citadel Advisors Llc	1.14%
Springbok Capital Management, LLC	1.09%
Geode Capital Management, LLC	1.00%
Vanguard Capital Management, LLC	0.99%
Morgan Stanley - Brokerage Accounts	0.89%
Philadelphia Trust Co	0.89%
Renaissance Technologies Corp	0.80%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Biovie Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.